GlassScriptPhysician profile
Holger E Bracht
NPI 1063481976
$4,043.22
in general payments reported to CMS, 2019-2025
31 companies · $794 in 2025
The $794 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $198 · 2021: $553 · 2022: $478 · 2023: $671 · 2024: $756 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $537.96 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.90 | 2021-2025 | Jardiance |
| Abbvie INC. | $451.10 | 2019-2025 | Ubrelvy |
| Amgen INC. | $305.05 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $271.64 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $265.46 | 2019-2024 | |
| Glaxosmithkline, LLC. | $253.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi Pasteur INC. | $169.84 | 2019-2024 | |
| Amarin Pharma, INC. | $163.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $130.70 | 2019-2025 | Breztri |
| Exact Sciences Corporation | $126.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $110.12 | 2022-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $105.03 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $65.01 | 2023-2024 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $49.19 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $46.27 | 2021 | |
| Viiv Healthcare Company | $43.66 | 2024-2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $37.73 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.59 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $34.66 | 2022 | |
| Allergan, INC. | $30.83 | 2019-2020 | |
| Gilead Sciences, INC. | $29.14 | 2024 | |
| Dexcom, INC. | $27.80 | 2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $26.08 | 2019-2020 | |
| Eisai INC. | $21.97 | 2022 | |
| Astellas Pharma US INC | $21.67 | 2019 | |
| Shire North American Group INC | $20.78 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.85 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $16.40 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holger Bracht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.